ROIV.O
ROIV.O- Latest Trade
- trading lower--
- --
- --
- As of Feb 1 2023. Values delayed up to 15 minutes
- Day Range
- -- - --
- 52-Week Range
- -- - --
- Previous Close
- 8.26
- Open
- 8.23
- Volume
- 1,461,964.00
- 3 Month Average Trading Volume
- 45.18
- Shares Out (Mil)
- 725.42
- Market Cap
- 5,991.96
- Forward P/E
- -5.99
- Dividend Yield
- 0.00
Key Statistics
1.66666667 mean rating - 9 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 118.85
- Price To Book (Quarterly)
- 5.01
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 35.48
- Long Term Debt/Equity (Quarterly)
- 32.40
- Return On Investment (TTM)
- -63.07
- Return On Equity (TTM)
- -47.65
2021 (millions USD)
About Roivant Sciences Ltd (ROIV.O)
Company Information
Roivant Sciences Ltd. is a pharma company. The Company is focused on developing transformative medicines that address areas of unmet medical need. The Company, through its subsidiaries, is focused on delivering medicines and technologies to patients. The Company builds biotech and healthcare technology companies (Vants) and deploys technology to drive research and development and commercialization. The Company’s product candidate includes VTAMA (tapinarof), IMVT-1401, Brepocitinib, Namilumab and RVT-2001. Its Vant family includes Dermavant, Immunovant, Priovant, Kinevant and Hemavant. Its small molecule discovery engine is powered by computational physics and machine learning (ML) capabilities for in silico drug design. The Company’s capabilities in diverse therapeutic areas, including immunology, dermatology and oncology, and modalities, including biologics, topicals and bifunctional small molecules.
Address
Clarendon House, 2 Church StreetHAMILTON,
HM11
Bermuda
Industry
Biotechnology & Drugs
Executive Leadership
- Vivek Ramaswamy
- Executive Chairman of the Board, Founder
- Eric Venker
- President, Chief Operating Officer
- Mayukh Sukhatme
- President, Chief Investment Officer
- Matthew Gline
- Chief Executive Officer, Director
- Richard Pulik
- Chief Financial Officer
- Rakhi Kumar
- Chief Accounting Officer
- Hiroshi Nomura
- Director
- Melissa B. Epperly
- Independent Director
- Daniel Gold
- Independent Director
- Keith S. Manchester
- Independent Director
- James C. Momtazee
- Independent Director
- Ilan Oren
- Independent Director
Latest News
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,924.70 | 0.25% |
| Copper | 787.60 | -- |
| Brent Crude Oil | 85.46 | -- |
| CBOT Soybeans | 1,535.50 | 0.16% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,076.60 | 1.46% |
| Euro STOXX 50 | 4,163.45 | 0.12% |
| FTSE 100 | 7,771.70 | 0.17% |
| Nikkei 225 | 27,376.22 | 0.18% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes